Free Newsletter
J&J unit recalls more OTC products
Johnson & Johnson's (NYSE: JNJ) embattled McNeil Consumer Healthcare unit is recalling 21 lots of OTC medicines sold in the U.S., Fiji, Guatemala, Dominican Republic, Puerto Rico, Trinidad & Tobago and Jamaica. Affected products include Benadryl allergy ultratab, Motrin IB and Children's Tylenol meltaways.
This action is a follow-up to a product recall originally announced on Jan. 15 that was initiated following consumer complaints of a musty or moldy odor linked to the presence of trace amounts of a chemical called 2,4,6-tribromoanisole.
These lots are being added to the list of recalled products as a precautionary measure after a continuing internal review determined that some packaging materials used in the lots had been shipped and stored on the same type of wooden pallet that was tied to the presence of TBA in earlier recalled lots, the company says in a statement. All lots involved in the recall were produced before the January recall.
As CNNMoney notes, this is the fifth recall in nine months for McNeil, which has drawn the FDA's ire for not reacting quickly to customer complaints.
- read the company's release
- check out CNNMoney's coverage
Related Articles:
J&J expects plant fixes to take all year
J&J's stock dips in wake of recall
J&J has suffered GMP collapse
Bad bottles, labels, drive two more Tylenol recalls
FDA cites botches in Tylenol odor probe
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: